Document ID: chunk:federal_register_of_legislation:F2024L01389:schedule:1:p44
Version: federal_register_of_legislation:F2024L01389
Segment Type: schedule
Provision Reference: sch 1 (pt 44/66)
Character Range: 120746–124535

"C14310"
[394] Schedule 4, Part 1, entry for Circumstances Code "C14318"
insert in alphabetical order in the column headed "Listed Drug": Apixaban
[395] Schedule 4, Part 1, omit entry for Circumstances Code "C14348"
[396] Schedule 4, Part 1, omit entry for Circumstances Code "C14350"
[397] Schedule 4, Part 1, omit entry for Circumstances Code "C14472"
[398] Schedule 4, Part 1, entry for Circumstances Code "C14872"
insert in alphabetical order in the column headed "Listed Drug": Sevelamer
[399] Schedule 4, Part 1, entry for Circumstances Code "C14895"
(a) insert in alphabetical order in the column headed "Listed Drug": Anastrozole
(b) insert in alphabetical order in the column headed "Listed Drug": Exemestane
(c) insert in alphabetical order in the column headed "Listed Drug": Letrozole
[400] Schedule 4, Part 1, omit entry for Circumstances Code "C14943"
[401] Schedule 4, Part 1, omit entry for Circumstances Code "C14984"
[402] Schedule 4, Part 1, omit entry for Circumstances Code "C14992"
[403] Schedule 4, Part 1, entry for Circumstances Code "C15269"
insert in alphabetical order in the column headed "Listed Drug": Dapagliflozin with sitagliptin
[404] Schedule 4, Part 1, entry for Circumstances Code "C15270"
insert in alphabetical order in the column headed "Listed Drug": Dapagliflozin with sitagliptin
[405] Schedule 4, Part 1, omit entry for Circumstances Code "C15355"
[406] Schedule 4, Part 1, omit entry for Circumstances Code "C15356"
[407] Schedule 4, Part 1, omit entry for Circumstances Code "C15358"
[408] Schedule 4, Part 1, omit entry for Circumstances Code "C15385"
[409] Schedule 4, Part 1, omit entry for Circumstances Code "C15439"
[410] Schedule 4, Part 1, after entry for Circumstances Code "C15952"
insert:
C15955  P15955  CN15955  Lanreotide                   Functional carcinoid tumour                                                                                                                                                                                                                                                                                                                                                                                         Compliance with Authority Required procedures - Streamlined Authority Code 15955
                                                      Continuing treatment
                                                      Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND
                                                      The condition must be causing intractable symptoms; AND
                                                      Patient must have experienced on average over 1 week, 3 or more episodes per day of diarrhoea and/or flushing, which persisted despite the use of anti-histamines, anti-serotonin agents and anti-diarrhoea agents; AND
                                                      Patient must be one in whom surgery or antineoplastic therapy has failed or is inappropriate; AND
                                                      The treatment must cease if there is failure to produce a clinically significant reduction in the frequency and severity of symptoms after 3 months' therapy at a dose of 120 mg every 28 days.
                                                      Dosage and tolerance to the drug should be assessed regularly and the dosage should be titrated slowly downwards to determine the minimum effective dose.
C15956  P15956  CN15956  Auranofin                    For prescribing by certain health practitioners
                         Chlorpromazine               Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a